RETROSPECTIVE STUDY OF ERLOTINIB IN PREVIOUSLY TREATED NSCLC PATIENTS WITH WILD-TYPE EGFR

被引：0

作者：

Nakahara, Yoshiro ^{[1
]}

Hosomi, Yukio ^{[1
]}

Yomota, Makiko ^{[1
]}

Okuma, Yusuke ^{[1
]}

Takagi, Yusuke ^{[1
]}

Iguchi, Mari ^{[1
]}

Okamura, Tatsuru ^{[1
]}

机构：

[1] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Thorac Oncol & Resp Med, Tokyo, Japan

来源：

JOURNAL OF THORACIC ONCOLOGY | 2012年 / 7卷 / 11期

关键词：

wild-type EGFR; Erlotinib;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P2-034

引用

页码：S490 / S490

页数：1

共 50 条

[41] Long-Term Treatment with Erlotinib for EGFR Wild-Type Non-Small Cell Lung Cancer: A Case Report
Polychronidou, Genovefa
Papakotoulas, Pavlos
CASE REPORTS IN ONCOLOGY, 2013, 6 (01): : 189 - 196
[42] Epithelial phenotype as a predictive marker for response to EGFR-TKIs in non-small cell lung cancer patients with wild-type EGFR
Ren, Shengxiang
Su, Chunxia
Wang, Zhaoye
Li, Jiayu
Fan, Lihong
Li, Bing
Li, Xuefei
Zhao, Cao
Wu, Chunyan
Hou, Likun
He, Yayi
Gao, Guanghui
Chen, Xiaoxia
Ren, Jiawei
Li, Aiwu
Xu, Guotong
Zhou, Xiao
Zhou, Caicun
Schmid-Bindert, Gerald
INTERNATIONAL JOURNAL OF CANCER, 2014, 135 (12) : 2962 - 2971
[43] A Randomized Phase II Study of Erlotinib Plus Nab-Paclitaxel Versus Erlotinib Alone as Second-Line Therapy for Chinese Patients with Advanced EGFR Wild-Type Non-Small-Cell Lung Cancer
Zhang, Yong
Gao, Chao
Qu, Wei
Gao, Yongsheng
Zhu, Shouhui
Zhang, Shuo
He, Wei
Yu, Yonghua
CANCER INVESTIGATION, 2015, 33 (06) : 241 - 245
[44] The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib
Zou, Yiyu
Ling, Yi-He
Sironi, Juan
Schwartz, Edward L.
Perez-Soler, Roman
Piperdi, Bilal
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (06) : 693 - 702
[45] Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines
Andrea Cavazzoni
Roberta R Alfieri
Daniele Cretella
Francesca Saccani
Luca Ampollini
Maricla Galetti
Federico Quaini
Gallia Graiani
Denise Madeddu
Paola Mozzoni
Elena Galvani
Silvia La Monica
Mara Bonelli
Claudia Fumarola
Antonio Mutti
Paolo Carbognani
Marcello Tiseo
Elisabetta Barocelli
Pier Giorgio Petronini
Andrea Ardizzoni
Molecular Cancer, 11
[46] Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines
Cavazzoni, Andrea
Alfieri, Roberta R.
Cretella, Daniele
Saccani, Francesca
Ampollini, Luca
Galetti, Maricla
Quaini, Federico
Graiani, Gallia
Madeddu, Denise
Mozzoni, Paola
Galvani, Elena
La Monica, Silvia
Bonelli, Mara
Fumarola, Claudia
Mutti, Antonio
Carbognani, Paolo
Tiseo, Marcello
Barocelli, Elisabetta
Petronini, Pier Giorgio
Ardizzoni, Andrea
MOLECULAR CANCER, 2012, 11
[47] Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma
Jackman, David M.
Kindler, Hedy L.
Yeap, Below Y.
Fidias, Panos
Salgia, Ravi
Lucca, Joan
Morse, Linda K.
Ostler, Patricia A.
Johnson, Bruce E.
Janne, Pasi A.
CANCER, 2008, 113 (04) : 808 - 814
[48] Serum Albumin in Patients with Advanced-Stage NSCLC Treated with Erlotinib
Fiala, Ondrej
Pesek, Milos
Finek, Jindrich
Racek, Jaroslav
Minarik, Marek
Benesova, Lucie
Topolcan, Ondrej
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S545 - S546
[49] Prospective Feasibility Study of Amrubicin and Bevacizumab Therapy for Patients With Previously Treated Advanced NSCLC
Imai, Hisao
Kaira, Kyoichi
Naruse, Ichiro
Kasahara, Norimitsu
Kamide, Yosuke
Ono, Akihiro
Masuda, Tomomi
Sunaga, Noriaki
Minato, Koichi
Hisada, Takeshi
ANTICANCER RESEARCH, 2020, 40 (03) : 1571 - 1578
[50] A Randomized Phase 2 Trial of Cabozantinib, Erlotinib or the Combination as 2nd or 3rd Line Therapy in EGFR Wild-Type NSCLC: ECOG-ACRIN E1512
Neal, Joel W.
Dahlberg, Suzanne E.
Wakelee, Heather A.
Aisner, Seena C.
Bowden, Michaela
Carbone, David P.
Ramalingam, Suresh S.
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S373 - S373

← 1 2 3 4 5 →